Lymphatic mapping and sentinel lymphadenectomy for breast cancer

A E Giuliano, D M Kirgan, J M Guenther, D L Morton, A E Giuliano, D M Kirgan, J M Guenther, D L Morton

Abstract

Objective: The authors report the feasibility and accuracy of intraoperative lymphatic mapping with sentinel lymphadenectomy in patients with breast cancer.

Summary background data: Axillary lymph node dissection (ALND) for breast cancer generally is accepted for its staging and prognostic value, but the extent of dissection remains controversial. Blind lymph node sampling or level I dissection may miss some nodal metastases, but ALND may result in lymphedema. In melanoma, intraoperative lymph node mapping with sentinel lymphadenectomy is an effective and minimally invasive alternative to ALND for identifying nodes containing metastases.

Methods: One hundred seventy-four mapping procedures were performed using a vital dye injected at the primary breast cancer site. Axillary lymphatics were identified and followed to the first ("sentinel") node, which was selectively excised before ALND.

Results: Sentinel nodes were identified in 114 of 174 (65.5%) procedures and accurately predicted axillary nodal status in 109 of 114 (95.6%) cases. There was a definite learning curve, and all false-negative sentinel nodes occurred in the first part of the study; sentinel nodes identified in the last 87 procedures were 100% predictive. In 16 of 42 (38.0%) clinically negative/pathologically positive axillae, the sentinel node was the only tumor-involved lymph node identified. The anatomic location of the sentinel node was examined in the 54 most recent procedures; ten cases had only level II nodal metastases that could have been missed by sampling or low (level I) axillary dissection.

Conclusions: This experience indicates that intraoperative lymphatic mapping can accurately identify the sentinel node--i.e., the axillary lymph node most likely to contain breast cancer metastases--in some patients. The technique could enhance staging accuracy and, with further refinements and experience, might alter the role of ALND.

References

    1. Eur J Surg Oncol. 1986 Sep;12(3):267-71
    1. Eur J Surg Oncol. 1986 Jun;12(2):169-73
    1. Eur J Surg Oncol. 1988 Oct;14(5):407-12
    1. Eur J Surg Oncol. 1990 Apr;16(2):127-33
    1. Br J Surg. 1990 Jul;77(7):760-4
    1. Acta Oncol. 1990;29(6):721-5
    1. Arch Surg. 1991 Nov;126(11):1336-41; discussion 1341-2
    1. Arch Surg. 1992 Apr;127(4):392-9
    1. Ann R Coll Surg Engl. 1992 Mar;74(2):126-9
    1. Lancet. 1992 May 23;339(8804):1245-8
    1. Acta Oncol. 1992;31(1):29-35
    1. J Surg Oncol. 1992 Sep;51(1):8-13
    1. Br J Surg. 1993 Apr;80(4):457-8
    1. Cancer. 1993 Jun 15;71(12):3920-5
    1. Br J Surg. 1976 Aug;63(8):569-75
    1. Cancer. 1987 Feb 15;59(4):682-7
    1. Am J Surg. 1993 Nov;166(5):502-8
    1. Cancer. 1977 Feb;39(2):527-32
    1. Ann Surg. 1980 Aug;192(2):148-51
    1. Aust N Z J Surg. 1980 Dec;50(6):580-3
    1. Surg Gynecol Obstet. 1981 Jun;152(6):765-72
    1. Lancet. 1982 May 29;1(8283):1210-2
    1. Ann Surg. 1982 Sep;196(3):371-8
    1. Ann Surg. 1982 Dec;196(6):642-4
    1. Ann Surg. 1983 Mar;197(3):276-83
    1. Surg Gynecol Obstet. 1984 Mar;158(3):255-9
    1. Lymphology. 1984 Dec;17(4):118-23
    1. Br J Surg. 1985 May;72(5):365-7
    1. Br J Surg. 1985 May;72(5):368-9

Source: PubMed

3
订阅